157 related articles for article (PubMed ID: 37088886)
1. Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Kim M; Lin TC; Arora T; Zhao H; Balasubramanian A; Stad RK; O'Kelly J; Spangler L; Bradbury BD; Curtis JR
J Bone Miner Res; 2023 Jun; 38(6):829-840. PubMed ID: 37088886
[TBL] [Abstract][Full Text] [Related]
2. Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
McGrath LJ; Spangler L; Curtis JR; Ehrenstein V; Sørensen HT; Saul B; Levintow SN; Reams D; Bradbury BD; Brookhart MA
Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):854-863. PubMed ID: 32537883
[TBL] [Abstract][Full Text] [Related]
3. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
4. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of osteoporosis treatments in Germany.
O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis.
Curtis JR; Arora T; Liu Y; Lin TC; Spangler L; Brunetti VC; Stad RK; McDermott M; Bradbury BD; Kim M
J Bone Miner Res; 2024 May; ():. PubMed ID: 38753892
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
10. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
11. Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies.
Li W; Ning Z; Yang Z; Fan T; Yao M; Zhang W; Wang M; Wen A; Wang J
Arch Osteoporos; 2022 Jun; 17(1):84. PubMed ID: 35715524
[TBL] [Abstract][Full Text] [Related]
12. Denosumab versus zoledronic acid in elderly patients after hip fracture.
Kim SJ; Kim JW; Lee DW
J Orthop Surg (Hong Kong); 2022; 30(3):10225536221147082. PubMed ID: 36541833
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.
Zullo AR; Lee Y; Lary C; Daiello LA; Kiel DP; Berry SD
Osteoporos Int; 2021 Mar; 32(3):565-573. PubMed ID: 33411003
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Morkos M; Mahrous P; Casagrande A; Go MT; Husni H; Hanna M; Goel M; Bedrose S; Li D; Baim S
Endocr Pract; 2022 Oct; 28(10):1078-1085. PubMed ID: 35787466
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases.
Tan EH; Rathod-Mistry T; Strauss VY; O'Kelly J; Giorgianni F; Baxter R; Brunetti VC; Pedersen AB; Ehrenstein V; Prieto-Alhambra D
J Bone Miner Res; 2024 Apr; ():. PubMed ID: 38619297
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
Miller PD; Pannacciulli N; Malouf-Sierra J; Singer A; Czerwiński E; Bone HG; Wang C; Huang S; Chines A; Lems W; Brown JP
Osteoporos Int; 2020 Jan; 31(1):181-191. PubMed ID: 31776637
[TBL] [Abstract][Full Text] [Related]
17. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.
Choi NK; Solomon DH; Tsacogianis TN; Landon JE; Song HJ; Kim SC
J Bone Miner Res; 2017 Mar; 32(3):611-617. PubMed ID: 27736041
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Mori T; Crandall CJ; Fujii T; Ganz DA
Arch Osteoporos; 2021 Jul; 16(1):113. PubMed ID: 34264429
[TBL] [Abstract][Full Text] [Related]
20. Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
Burckhardt P; Faouzi M; Buclin T; Lamy O;
J Bone Miner Res; 2021 Sep; 36(9):1717-1728. PubMed ID: 34009703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]